Infinite Intelligence Pharma Completes Series Pre-A Financing

(VCBeat) Feb. 5, 2021 – Beijing-based Infinite Intelligence Pharma announced today that it had received investment in a Series Pre-A round from Zhuhai Lizon Pharmaceutical Private-Equity Investment Management Co., Ltd., a wholly-owned investment platform of Livzon Pharmaceutical Group Inc. (1513.HK, 000513.SZ).

Infinite Intelligence Pharma brings together the top domestic drug design and AI-based drug research experts, in the international early. The company is one of the first to apply AI technology to the R&D of new drugs at home and abroad. In the past one and a half years of development, Infinite Intelligence Pharma has transformed the team's successful accumulation of technical experience into PharmaMind, an AI-driven drug R&D system with independent intellectual property rights.

According to Infinite Intelligence Pharma, with the support of investments from CAS Star and WI Harper Group in the angel round in August 2019, the AI-based new drug development platform -- PharmaMind has already begun to take shape. 

The platform integrates the forefront technologies of AI-driven drug design (AIDD) and a new generation of computer-aided drug design (CADD) to cover the whole process from the discovery of targets to the R&D of preclinical candidates. PharmaMind can accurately calculate and predict the multi-dimensional properties of the designed compounds, significantly improve the R&D of innovative drugs and the success rate of early R&D fundamentally, which meets the urgent demand for increasing the efficiency of the pharmaceutical industry.

PharmaMind contains many leading practical technologies, including "based-on -system target discovery and combination analysis", "potential drug resistance mutation prediction of drug targets", "based-on-structure analysis of protein druggability", "based-on-structure three-dimensional molecular generation", "virtual high throughput screening with high precision", "high druggable compounds optimization", "multi-target design and optimization", "allosteric /IDP drug design" and "high-precise compound structure image recognition" and others.

Livzon established in January 1985 with registered capital of 953 million yuan, is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production and sales, with more than 9,000 employees. The company has more than 400 varieties of API, chemical drugs, proprietary Chinese medicines, biological drugs, biochemical drugs and diagnostic reagents, more than 90 varieties of which are produced and sold, involving digestive, cardio-cerebrovascular, reproductive endocrinology, psychotropic/neurological, anti-infectious, anti-tumor fields, etc.